AVALO THERAPEUTICS, INC.

Analyst Reco. Avalo Therapeutics, Inc.

Equities

AVTX

US05338F3064

Market Closed - Nasdaq Other stock markets 04:30:01 2024-05-03 pm EDT			5-day change	1st Jan Change
14.36 ^USD	-6.69%		-9.91%	+57.80%

Apr. 17	North American Morning Briefing : Stock Futures -2-	DJ
Apr. 16	Oppenheimer Upgrades Avalo Therapeutics to Outperform From Perform, Price Target is $35	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oppenheimer Upgrades Avalo Therapeutics to Outperform From Perform, Price Target is $35	Apr. 16	MT
Oppenheimer Downgrades Avalo Therapeutics to Perform From Outperform, Removes $10 Price Target	23-06-27	MT
Avalo Therapeutics Downgraded by RBC to Sector Perform From Outperform, Price Target Cut to $0.75 From $9, Speculative Risk Kept	23-06-27	MT
RBC Cuts Price Target on Avalo Therapeutics to $9 From $17, Maintains Outperform Rating, Speculative Risk Qualifier	23-05-10	MT
Jefferies Downgrades Avalo Therapeutics to Underperform From Hold, Lowers Price Target to $3 From $4.50	23-02-08	MT
Oppenheimer Adjusts Avalo Therapeutics Price Target to $10 From $17, Maintains Outperform Rating	22-11-09	MT
Oppenheimer Adjusts Avalo Therapeutics Price Target to $17 From $5, Maintains Outperform Rating	22-08-08	MT
RBC Cuts Price Target on Avalo Therapeutics to $17 From $21, Maintains Outperform Rating, Speculative Risk Qualifier	22-08-05	MT
RBC Cuts Price Target on Avalo Therapeutics to $21 From $24 After 1-for-12 Reverse Stock Split; Outperform, Speculative Risk Kept	22-07-11	MT
RBC Halves Price Target on Avalo Therapeutics to $2 From $4, Noting 'Early Stage Risk With Minimal Safeguards,' Keeps Outperform-Speculative Risk Rating	22-05-06	MT
Jefferies Downgrades Avalo Therapeutics to Hold from Buy, Adjusts Price Target to $0.75 from $5	22-03-03	MT
RBC Cuts Price Target on Avalo Therapeutics to $4 From $5, Maintains Outperform Rating, Speculative Risk Qualifier	22-03-03	MT
Oppenheimer Adjusts Avalo Therapeutics PT to $5 From $7, Maintains Outperform Rating	21-11-10	MT
AVALO THERAPEUTICS : RBC Initiates Avalo Therapeutics With Outperform Rating, Speculative Risk Qualifier, Sets Price Target at $6	21-09-24	MT
CERECOR : Cantor Fitzgerald Initiates Coverage on Cerecor With Overweight Rating, $7 Price Target	21-06-04	MT
CERECOR : Oppenheimer Adjusts Cerecor PT to $7 From $9 on Q1 Results and Ahead of Top-Line Data, Maintains Outperform Rating	21-05-24	MT
CERECOR : Maxim Upgrades Cerecor to Buy from Hold, Sets $7 Price Target	21-04-21	MT
CERECOR : Jefferies Initiates Cerecor at Buy with $4 Price Target	21-04-20	MT
CERECOR : Oppenheimer Adjusts Cerecor PT to $9 From $10, Maintains Outperform Rating	20-11-18	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

SIGN UP NOW